Pacira製藥 PCRX 深 滬
已收盤 12-19 16:00:00 美东时间
26.35
+0.470
+1.82%
華盛通- 最 高26.99
- 今 開25.80
- 成交量 254.45万股
- 最 低 25.80
- 昨 收 25.88
- 總市值 12.20亿
- 52周最高 27.64
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 18.17
- 委 比 90.89%
- 總股本 4630.47万
- 歷史最高 121.95
- 量 比 2.50
- 振 幅 4.60%
- 歷史最低 6.51
- 每 手 1
- 風險率 2.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
Barclays Initiates Coverage On Pacira BioSciences with Equal-Weight Rating, Announces Price Target of $27
Barclays analyst Glen Santangelo initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Equal-Weight rating and announces Price Target of $27.
12-10 00:04
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences announced inducement awards on December 1, 2025, to two new employees, granting them a total of 2,200 restricted stock units (RSUs) under its Amended and Restated 2014 Inducement Plan. The RSUs vest annually over four years beginning December 1, 2026, contingent on continued employment. Pacira, a leader in non-opioid pain therapies, offers products like EXPAREL®, ZILRETTA®, and iovera®°. Contact: Investor: Susan Mesco, Media: S...
12-03 13:00
Pacira Biosciences Files Patent Infringement Lawsuit In U.S. District Court Against The WhiteOak Group And Qilu Pharmaceutical Alleging Infringement Of Patents Related To EXPAREL, Pacira's Non-Opioid, Long-Acting Bupivacaine Liposome Injectable Used For Pain Management
Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has filed a patent infringement
11-27 05:05
美股大行评级 | Stifel上调特斯拉目标价升至508美元；多家大行上调Vita Coco目标价最高至58美元
今日重点评级关注：HC Wainwright & Co.：维持Oncolytics Biotech"买入"评级，目标价从5美元升至10美元；HC Wainwright & Co.：维持Barinthus Biotherapeutics"买入"评级，目标价从3美元升至4美元
11-18 15:28
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
Pacira BioSciences, Inc. announced its participation in two healthcare conferences: Jefferies London Healthcare Conference on November 18th at 1:30 PM GMT and the 37th Annual Piper Sandler Healthcare Conference on December 2nd at 1:30 PM ET. These events will feature analyst-led fireside chats, accessible live and via replay for two weeks on the company's website, investor.pacira.com. Pacira, a leader in non-opioid pain therapies, offers products...
11-11 13:00
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Pacira BioSciences Lowers FY2025 Sales Guidance from $730.000M-$750.000M to $725.000M-$735.000M vs $737.200M Est
Pacira BioSciences (NASDAQ:PCRX) lowers FY2025 sales outlook from $730.000 million-$750.000 million to $725.000 million-$735.000 million vs $737.200 million estimate.
11-07 05:13
Earnings Scheduled For November 6, 2025
Companies Reporting Before The Bell • Clear Channel Outdoor (NYSE:CCO) is expec...
11-06 19:12
